We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Canadian Researchers Identify Mutations Linked to Rare Form of Liver Cancer

By LabMedica International staff writers
Posted on 05 Jan 2015
Canadian cancer researchers working with patients in China have identified mutations linked to the development of intrahepatic cholangiocarcinoma (ICC), a rare, highly fatal form of liver cancer that disproportionately affects individuals of Asian origin.

ICC, also known as intrahepatic bile duct cancer, accounts for approximately 10% of primary liver malignancies worldwide, but while it strikes only about one in 100,000 people annually in North America, it causes 96 cases per 100,000 people annually in Thailand. More...
Prognosis for ICC patients is poor, as early tumors are usually undetectable due to being hidden in bile ducts located deep inside the body. Thus, the disease is diagnosed only after symptoms develop and the disease has advanced. There are no effective therapies for ICC, and the median survival duration after diagnosis is only six to nine months.

Investigators at Simon Fraser University (Burnaby, BC, Canada) sequenced tumor and matching control sample pairs of a large cohort of 103 Chinese ICC patients, which resulted in the identification of an ICC-specific somatic mutational signature that was associated with liver inflammation, fibrosis, and cirrhosis.

They further uncovered 25 significantly mutated genes including eight potential driver genes (TP53, KRAS, IDH1, PTEN, ARID1A, EPPK1, ECE2 and FYN). Three pathways (Ras/phosphatidylinositol-4,5-bisphosphate 3-kinase signaling, p53/cell cycle signaling, and transforming growth factor-beta/Smad signaling)—genes important for epigenetic regulation and oxidative phosphorylation—were found to be affected substantially in ICC.

"Our research is by far the most comprehensive sequencing effort to identify mutations associated with ICC and will be an important resource for scientists working to improve understanding and therapy for the disease," said contributing author Dr. Nansheng Chen, professor of molecular biology and biochemistry at Simon Fraser University. "Some cancer types, including ICC, are uncommon in Canada, which has a relatively small population but a large diversity of ethnic origins. To get insight into the formation of tumors in these rare cancer types, we have to establish international collaborations like ours to gain access to large sample cohorts. Results from this study could help us understand the driver mutations in Chinese Canadians with intrahepatic bile duct cancer. And our work illustrates that this is a real opportunity and sets up a model for working on rare disease conditions."

The study was published in the December 15, 2014, online edition of the journal Nature Communications.

Related Links:

Simon Fraser University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.